Publications of interest for August 2010
19 August 2010
Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group Study. Ribaudo HJ et al. JID 2010.
Haplotype structure of CYP2B6... more
News for March 2010
15 March 2010
Report on the pharmacogenetics presentations at the 17th Conference on Retroviruses and Opportunistic infections (http://www.retroconference.org).
Click here to view the report.
Click here to view... more
IL28B variation: a new determinant of hepatitis C virus natural and treatment-induced clearance.
24 January 2010
The last few months have seen a rush of key papers for the understanding of the role of innate immunity – and in particular of interferon lambda (encoded by IL28B). Three papers by Ge D et al (Nature ... more
The use of genetics to individualize therapy.
4 July 2009
The use of genetics to individualize therapy by A. Telenti. Södak Conference, 24-27 July 2009, St Gallen.
Click here to view the presentation ... more
Pharmacogenetics presentations at the 10th International Workshop on Clinical Pharmacology of HIV therapy
26 May 2009
Pharmacogenetics presentations at the 10th International Workshop on Clinical Pharmacology of HIV therapy. 15-17 April 2009, Amsterdam.
- The effect of multiple dose lopinavir/ritonavir on intestina... more
Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy
24 April 2009
Time (again) for a randomized trial of pharmacogenetics of antiretroviral therapy. Editorial commentary by A. Telenti. Pharmacogenomics 2009, 10: 515-516.
This editorial discuss the need for randomi... more
Report on the Pharmacogenetics presentations at the 16th Conference on Retroviruses and Opportunistic Infections
27 February 2009
Report on the Pharmacogenetics presentations at the 16th Conference on Retroviruses and Opportunistic Infections (http://www.retroconference.org/2009/), Montreal, February 8-11, 2009, by C. Marzolini.... more
New genome-wide studies on HIV-1 control of viral load and progression
4 February 2009
Following the 2007 publication by Fellay et al., a number of studies have completed additional genome-wide association studies on the determinants of viral and disease control. The study by Dalmasso e... more
Update on genetic determinants of susceptibility to HIV-1 – a need for a reappraisal
3 December 2008
This month sees the update of the table on “Natural Modifiers”, the listing of studies reporting on genetic associations with susceptibility to HIV-1, with viral load or CD4 dynamics, or with progress... more
Genetics of HIV lipodystrophy
12 October 2008
Body fat changes and other metabolic complications (collectively known as HIV lipodystrophy syndrome) have been linked to antiretroviral therapy and HIV infection itself. However these manifestations ... more
HCP5 screening to predict abacavir hypersensitivity reaction
28 August 2008
Several studies have shown that the HLA-B*5701 allele is associated with abacavir hypersensitivity reaction (ABC-HSR). The current gold standard in screening for HLA-B*5701 is the sequence-based genot... more
Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions
23 July 2008
Surveillance of (severe) adverse reactions could be coupled to an active program of pharmacogenomics. This could allow the identification of the biological basis of toxicity, and facilitate the use of... more
Pharmacogenetics presentations at the 9th International Workshop on Clinical Pharmacology of HIV Therapy
22 April 2008
Pharmacogenetics presentations at the 9th International Workshop on Clinical Pharmacology of HIV Therapy( http://www.hivpresentation.com/ ) New Orleans, April 7-9, 2008.
Links to the pharmacogenetic... more
Novel strategy for the discovery of genes associated with disease susceptibility
14 March 2008
Previous candidate gene-based pharmacogenetics approaches required a priori knowledge and the selection of a small number of candidate genes for hypothesis testing. Current strategies use genome-wide ... more
Report on the pharmacogenetics presentations at the 15th CROI
17 February 2008
Report on the pharmacogenetics presentations at the 15th Conference on Retroviruses and Opportunistic Infections (www.retroconference.org) Boston, February 3-6 2008 by A. Owen and C. Marzolini.
Clic... more
Genetic polymorphisms associated with hyperlipidemia, diabetes mellitus type 2, and obesity in genome-wide association analyses
21 December 2007
Genetic polymorphisms associated with hyperlipidemia, diabetes mellitus type 2, and obesity in genome-wide association analyses by P. Tarr and A Telenti.
Metabolic disorders remain a main considerati... more
Detection of genome variations affecting gene expression
9 November 2007
Understanding the genetic control mechanisms of gene expression might allow to identify functional elements of the human genome and ultimately reveal polymorphisms relevant to disease susceptibility. ... more
Copy number variation in genes
10 October 2007
Extensive studies are currently being performed to associate pharmacokinetic variability or disease susceptibility with single nucleotide polymorphisms. However, during the last few years, another typ... more
Genetics of dyslipidemia
4 September 2007
Dyslipidemia, which is characterized by elevated total and non-HDL-cholesterol, hypertriglyceridemia and low HDL-cholesterol, is common in HIV-infected patients who are treated with long-term antiretr... more
Genome-wide association studies for the identification of genetic markers of disease pathogenesis
6 August 2007
Genome-wide association (GWA) studies have become feasible with the availability of the human genome sequence and the development of SNP genotyping technologies with high throughput and affordable cos... more
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
12 July 2007
Desta et al investigated the impact of CYP2B6 polymorphism on hepatic efavirenz (EFV) metabolism in vitro. Eighty-seven liver samples from individuals of Caucasian origin were genotyped for 16 functio... more
Genomics in the limelight
17 June 2007
The field of whole genome association analysis (WGA) is exploding. Since late 2006, the trickle of successful WGA is becoming a steady flow. The most recent paper by The Wellcome Trust Case Contr... more
Pharmacogenetic information derived from analysis of HLA alleles
15 May 2007
The pathogenesis of a number of multi-system drug hypersensitivity reactions involves major histocompatibility complex (MHC)-restricted presentation of drug or drug metabolites to MHC molecules and/or... more
Report on the pharmacogenetics presentations at the 14th CROI
12 April 2007
Report on the pharmacogenetics presentations at the 14th Conference on Retroviruses and Opportunistic Infections (www.retroconference.org), Los Angeles, February 25-28, 2007 by Andrew Owen.
Click her... more
CYP2B6: explaining efavirenz pharmacokinetics
9 February 2007
The relatively “new” isoenzyme CYP2B6 is characterized by wide interindividual variability in hepatic expression and activity. Recent pharmacogenetic studies suggest that CYP2B6 is highly polymorphic ... more
Towards understanding the meaning of MDR1 3435C>T
8 February 2007
The ABCB1 (MDR1) gene, encoding the transporter P-glycoprotein, is known to act on a broad range of prescription medicines. For this reason a large number of studies have assessed the functional conse... more
New bioinformatics tools in Genomics
12 January 2007
Increasing availability of genetic variation data (ie. SNPs), and improvements in high throughput analysis generates a new demand for bioinformatics and analytical tools. Two important tools have been... more
Genetic studies in clinical trials and observational cohorts
7 December 2006
Summary: Pharmacogenomic research strives to understand the influence of human genetics on interindividual variability in response to medications. This field holds great promise to improve treatment o... more
Effect of orosomucoid variants on protease inhibitors pharmacokinetics
6 November 2006
Orosomucoid (ORM) or alpha-1-acid glycoprotein is an important determinant of the plasma binding of many basic drugs such as protease inhibitors. ORM concentration can increase considerably in stressf... more
Conference report: 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
5 October 2006
Report on pharmacogenetics and host genetics presentations at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 27-30, 2006.
Click here to view the ... more
Genetics of immune reconstitution
2 October 2006
Antiretroviral therapy typically brings substantial immune reconstitution. However, in a number of subjects a discrepancy between plasma viral load and the CD4 lymphocyte count recovery is observed. C... more
XVI International AIDS Conference: abstracts of interest
4 September 2006
-Polymorphisms of CCR5 and CCR2 genes associated with HIV-1 resistance in Mongolia. Amarjargal Y et al. View the abstract.
- Analysis of the CCR5 gene T303A polymorphism in Mayan and Mestizo p... more
Conference report XVI International AIDS Conference
2 September 2006
Toronto Canada 13-18 August 2006
http://www.aids2006.org/
CCR5 polymorphisms still in the limelight
Studies from HIV infected and uninfected populations from Mongolia, Mexico, Rwanda, India, Bra... more
Genetic factors in the predisposition to nevirapine hypersensitivity
1 September 2006
Nevirapine has been associated with hypersensitivity reactions involving various combinations of fever, hepatitis or rash. Nevirapine-associated hypersensitivity occurs within 14 to 21 days of treatme... more
Genetic factors in the susceptibility of NRTIs-induced peripheral neuropathy
31 July 2006
Nucleoside reverse transcriptase inhibitors (NRTIs) can cause peripheral neuropathy that is characterized by distal sensory polyneuropathy with painful dysesthesia and sensory loss. Peripheral neuropa... more
Creation of a consortium on genomics of HIV susceptibility
22 June 2006
Through a new consortium, investigators will share access to HIV patients cohorts in order to perform large scale analysis of genetic differences among HIV-infected patients. Support for the consortiu... more
Report on the PGx presentations at the 7th Int workshop on pharmacology
8 May 2006
Report on the pharmacogenomics presentations at the 7th international workshop on pharmacology, Lisbon, Portugal, April 2006 by David Back.
Click here to view the report... more
Ethnic differences for P450 enzymes
13 April 2006
Geographic patterns of genetic variation indicate that geographic structuring of inter-individual variation in drug concentrations and response may occur (Wilson et al. Nat Genet 29:265-9, 2001). This... more
Genetic polymorphisms of CYP2B6 and efavirenz drug levels
8 March 2006
The paper by Wang et al identified a new haplotype in CYP2B6 (983T>C and 785A>G, i.e. CYP2B6*16) that is related to high efavirenz plasma levels. CYP2B6 was considered to be of minor importance for dr... more
Reports on the 13th CROI
14 February 2006
Reports on the pharmacogenetic and genetics of host susceptibility presentations at the 13th Conference on Retroviruses and Opportunistic Infections, 2/5/06-2/8/06, Denver, Colorado.
Click below for... more
Report on the 45th ICAAC
24 January 2006
Report on the pharmacogenetic studies presented at the 45th annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, december 2005.... more
Genetic polymorphisms of CYP3A5 and saquinavir metabolism
19 January 2006
The paper by Mouly et al demonstrates a role for CYP3A5 in saquinavir metabolism. CYP3A5 is a hepatic and intestinal enzyme that is closely related to CYP3A4. Unlike CYP3A4, CYP3A5 is polymorphic. Int... more
Guidelines for the design, execution and analysis of gene association studies
1 December 2005
The number of genetic association studies is growing rapidly, and this growth is likely to accelerate in the future. There is increasing awareness that the literature of association studies requires t... more
First edition of the catalogue of human diversity
2 November 2005
The first edition of the catalogue of human diversity is complete After the completion of the human genome sequence, many of the leading genome centers concentrated on examining and cataloguing human ... more
Hyperbilirubinemia
1 October 2005
The papers by Rotger et al and Zhang et al respectively discuss the issue of hyperbilirubinemia in relation to UGT1A1 polymorphism, the microsomal enzyme responsible to mediate bilirubin conjugation w... more
Host genetics and HIV-1 susceptibility - Moving to the front line
12 September 2005
Today, several research groups study host genetic differences aiming at using this knowledge to better understand the basis of human susceptibility to HIV-1, explore the pathogenesis of the disease, i... more
Mitochondrial toxicity
1 September 2005
The paper by Hulgan et al, revisits the issue of mitochondrial role of toxicities such as lipoatrophy, myopathy, and in this particular paper, neuropathy. A hypothesis, is that sequence variants that ... more
Report on the IAS conference on HIV pathogenesis and treatment
17 August 2005
Report on the pharmacogenetic studies presented at the IAS conference on HIV pathogenesis and treatment - Rio de Janeiro 24-27 July 2005 .... more
Nomenclature recommendations
17 August 2005
This document summarize the actual recommandations for genetic nomenclature.... more
Clinical relevance of advances in Pharmacogenomics
1 August 2005
This is an interesting report about pharmacogenomics and its impact on the management of person with HIV by Stephen L. Becker, MD.... more
Human susceptibility to HIV-1 infection or progression of disease database
20 July 2005
HIV-Pharmacogenomics.org releases a new resource on genes and alleles that modify human susceptibility to HIV-1 infection or progression of disease. This information may eventually help predict the be... more
Report on pharmacogenetics of antituberculous agents
6 July 2005
Discussion on pharmacogenetics of antituberculous agents by Andrew Owen.... more
Report on Pharmacogenomic Presentations at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, February 2005
9 May 2005
A total of 12 presentations assessed the impact of host genotype on the pharmacokinetics (PK) or outcome of antiretroviral therapy. 2 were oral communications and the remainder poster presentations. ... more